WHWK Company Profile and Key Details

WHWK has shown sold momentum, gaining 11.28% over the past week and 29.41% over the past quarter, though year-to-date performance is up 18.18%. Short-term trend indicators are bearishly aligned (SMA20 11.09%, SMA50 18.35%, SMA200 49.49%). The stock’s 14-day RSI is 66.05 (firm momentum), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.79% below its high and over 133.81% above its low. Average 10-day trading volume of 224.47 thousand shares is significantly above the 3-month average of 135.00 thousand, indicating heightened recent market interest.

Whitehawk Therapeutics Inc generated EPS of $0.14 over the past year. Five-year average earnings growth is 22.81%. Wall Street analysts project EPS growth of 18.93% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $7.00. The high target offers 86.67% upside. The low target suggests 86.67% downside. The mean target is $7.00. This offers 86.67% upside. Whitehawk Therapeutics Inc earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -49.02%. The prior quarter beat by -255.1%. Over the last six quarters, Apple has recorded several small beats. These include 204.55% in March 18, 2025.

Whitehawk Therapeutics Inc has 47.13 million shares outstanding. The public float is 18.95 million shares, elevated short interest at 0.69% of float. This equals 242.69 thousand shares. The short ratio is 2.4 days. Institutional investors hold 76.81% of the float. Insiders own 12.43%.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Our AI price prediction model suggests that Whitehawk Therapeutics Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.8%, with price expected at $4.08 by March 20, 2026, within a range of $3.97 to $4.19 3-Month Outlook: Projected fall of -45.87%, reaching $2.03 by June 04, 2026, with a range of $1.99 to $2.07. 1-Year Outlook: Projected gain of 621.33%, with price at $27.05 by March 05, 2027, within a range of $27.02 to $27.08.

Whitehawk Therapeutics Inc (NASDAQ:WHWK) shares are up 18.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Whitehawk Therapeutics Inc trading at a premium to the broader market with a P/E of -16.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.00, suggesting 86.67% upside. Our AI forecast model points to short-term strength (8.8% over two weeks), a medium-term fall (-45.87% over three months), and a longer-term gain (621.33% over one year), with expected trading ranges indicating moderate volatility.

Whitehawk Therapeutics Inc (NASDAQ:WHWK) closed at $3.75 USD, gaining $0.18 (5.04%) from the previous close of $3.57. The stock is currently within 5% of its 52-week high $1.39 and $3.93. With a market capitalization of about $176.73 million, Whitehawk Therapeutics Inc is classified as a micro-cap and shows lower-than-market volatility (beta ~0.64). Key stats such as the average daily volume over the past year has been around 133.30 thousand shares, trading with heavier-than-usual volume. Headquartered in Pacific Palisades, CA, Whitehawk Therapeutics Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO David J. Lennon, the company employs approximately 40 people and listed since August 01, 2017. Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company.

Whitehawk Therapeutics Inc trades at a P/E ratio of -16.21, slightly below the S&P 500 average, with a price-to-sales ratio of 12.15 and a price-to-book ratio of 1.61 suggesting the stock is closer to book value. The P/FCF stands at -1.82, also above market averages.